Please assess the completion status of the following clinical trial:

Trial Title: Soy Isoflavones in Preventing Head and Neck Cancer Recurrence in Patients With Stage I-IV Head and Neck Cancer Undergoing Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have pathologically-confirmed, resectable, squamous cell carcinoma of the oral cavity, oropharynx, larynx or hypopharynx~* Disease must be Stage I, II, III or IVa~* Tumor must be potentially surgically resectable and curable with conventional surgery and radiation therapy~* Eastern Cooperative Oncology Group (ECOG) Performance status 0-2~* Patients must give documented informed consent to participate in this study~Exclusion Criteria:~* Documented evidence of distant metastases~* Ongoing acute medical condition such as uncontrolled coronary artery disease, emphysema, or diabetes mellitus that would preclude surgical resection~* Pregnancy or lactation; patients of child bearing age must agree to use adequate contraception (hormonal or barrier method of birth control) prior to study entry and for the duration of soy administration~* A medical or psychiatric illness which would compromise the patient's ability to tolerate this treatment or comply with administration of study drug~* Patients residing in prison~* Any patient with a history of breast or ovarian cancer~* Allergy to soy products

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Treatment (soy isoflavones) (Type: EXPERIMENTAL): Patients receive soy isoflavones PO for approximately 14 days before undergoing surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).